XLRN - アクセルロン・ファ―マ (Acceleron Pharma Inc.) アクセルロン・ファ―マ

 XLRNのチャート


 XLRNの企業情報

symbol XLRN
会社名 Acceleron Pharma Inc. (アクセルロン・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アクセルロン・ファーマ(Acceleron Pharma Inc.)は臨床段階のバイオ医薬品会社である。同社は希少疾患の治療法の発見、開発及び製品化に取り組む。同社の研究は人全身の組織の成長と修復に重要な調節因子である分子群の形質転換増殖因子β(TGF-b) タンパク質スーパーファミリーの生物学に重点を置く。同社はluspatercept、sotatercept、dalanterceptおよびACE-083を含む臨床試験中の4つの内部発見治療候補を含む。同社はプラットフォーム技術IntelliTrapを提供する。同社はまた線維性成分による障害の治療のための選択的TGF-βアンタゴニストであるACE-1332、非公開治療領域のIntelliTrapプラットフォームからの追加分子を評価する。Dalanterceptは、ALK1受容体を介したシグナル伝達を阻害して血管形成を阻害することによって癌を治療するように設計される。ACE-083は筋肉の成長を促進し、特定の標的筋肉で機能するように設計される。   アクセルロン・ファ―マは、米国のバイオ医薬品会社。癌および希少疾患のためのタンパク質治療薬の発見、開発、商業化に注力する。セルジ―ン社と共同で、貧血と関連する合併症の治療のために、タンパク質治療薬候補「Sotatercept」と「ACE-536」を開発する。また、癌患者の治療に「Dalantercept」を開発している。   Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
本社所在地 128 Sidney Street Cambridge MA 02139 USA
代表者氏名 Francois E. Nader フランソワ・イー・ネイダー
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-649-9200
設立年月日 37773
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 139人
url www.acceleronpharma.com
nasdaq_url https://www.nasdaq.com/symbol/xlrn
adr_tso
EBITDA EBITDA(百万ドル) -108.29400
終値(lastsale) 52.505
時価総額(marketcap) 2415359529.835
時価総額 時価総額(百万ドル) 2313.924
売上高 売上高(百万ドル) 13.63600
企業価値(EV) 企業価値(EV)(百万ドル) 225.994
当期純利益 当期純利益(百万ドル) -108.53600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Acceleron Pharma Inc revenues increased 2% to $6.9M. Net loss decreased less than 1% to $55.2M. Revenues reflect Collaboration Revenue : Cost-Sharing Ne increase of 7% to $6.9M. Net loss reflects Stock-based Compensation in SGA decrease of 37% to $5.7M (expense) Interest Income increase from $978K to $2.7M (income) Stock-based Compensation in R&D decrease of 17% to $5.9M (expense).

 XLRNのテクニカル分析


 XLRNのニュース

   Acceleron Pharma Inc (XLRN): Price Now Near $129.12; Daily Chart Shows An Uptrend on 20 Day Basis  2021/09/02 15:18:41 ETF Daily News
It''s been a feast for bears operating on an hourly timeframe, as xlrn has now gone down 8 of the past 10 hours. The post Acceleron Pharma Inc (XLRN): Price Now Near $129.12; Daily Chart Shows An Uptrend on 20 Day Basis appeared first on ETF Daily News .
   Leerink Partners Stick to Their Hold Rating for Acceleron Pharma By Investing.com  2021/08/08 13:12:29 Investing.com
Leerink Partners Stick to Their Hold Rating for Acceleron Pharma
   Acceleron Pharma Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/06 14:36:45 Seeking Alpha
   Transforming Growth Factor Beta 1 Market Will Touch New Level in Upcoming Year by Roche, Shionogi Ltd, Acceleron Pharma Inc  2021/07/15 18:45:20 Tramways Monthly
Transforming Growth Factor Beta 1 Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied []
   Here is What Hedge Funds Think About Acceleron Pharma Inc (XLRN)  2021/07/06 04:19:10 Insider Monkey
   Acceleron Pharma Inc (XLRN): Price Now Near $129.12; Daily Chart Shows An Uptrend on 20 Day Basis  2021/09/02 15:18:41 ETF Daily News
It''s been a feast for bears operating on an hourly timeframe, as xlrn has now gone down 8 of the past 10 hours. The post Acceleron Pharma Inc (XLRN): Price Now Near $129.12; Daily Chart Shows An Uptrend on 20 Day Basis appeared first on ETF Daily News .
   Leerink Partners Stick to Their Hold Rating for Acceleron Pharma By Investing.com  2021/08/08 13:12:29 Investing.com
Leerink Partners Stick to Their Hold Rating for Acceleron Pharma
   Acceleron Pharma Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/06 14:36:45 Seeking Alpha
   Transforming Growth Factor Beta 1 Market Will Touch New Level in Upcoming Year by Roche, Shionogi Ltd, Acceleron Pharma Inc  2021/07/15 18:45:20 Tramways Monthly
Transforming Growth Factor Beta 1 Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied []
   Here is What Hedge Funds Think About Acceleron Pharma Inc (XLRN)  2021/07/06 04:19:10 Insider Monkey
   Leerink Partners Stick to Their Hold Rating for Acceleron Pharma By Investing.com  2021/08/08 13:12:29 Investing.com
Leerink Partners Stick to Their Hold Rating for Acceleron Pharma
   Acceleron Pharma Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/06 14:36:45 Seeking Alpha
   Transforming Growth Factor Beta 1 Market Will Touch New Level in Upcoming Year by Roche, Shionogi Ltd, Acceleron Pharma Inc  2021/07/15 18:45:20 Tramways Monthly
Transforming Growth Factor Beta 1 Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied []
   Here is What Hedge Funds Think About Acceleron Pharma Inc (XLRN)  2021/07/06 04:19:10 Insider Monkey
   Study of ACE-1334 to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Efficacy in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease  2021/07/02 16:00:00 Clinical Trials Gov
Condition : Systemic Sclerosis With and Without Interstitial Lung Disease Interventions : Drug: ACE-1334; Drug: Placebo Sponsor : Acceleron Pharma Inc. Not yet recruiting

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アクセルロン・ファ―マ XLRN Acceleron Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)